EverSource Wealth Advisors’s Zevra Therapeutics ZVRA Stock Holding History

EverSource Wealth Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$516	Buy	36 +16	+80%	+$178	﹤0.01%	4122
2026 Q1	$185	Buy	20 +11	+122%	+$99	﹤0.01%	4210
2025 Q4	$81	Buy	9 +2	+29%	+$19	﹤0.01%	4128
2025 Q3	$67	Sell	7 -3	-30%	-$30	﹤0.01%	4233
2025 Q2	$88	Sell	10 -4	-29%	-$32	﹤0.01%	4145
2025 Q1	$105	Buy	14 +9	+180%	+$72	﹤0.01%	3821
2024 Q4	$42	Buy	+5	New	+$43	﹤0.01%	3655

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EverSource Wealth Advisors's ZVRA Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Zevra Therapeutics (ZVRA) stake by 80% in Q2 2026, buying an estimated $178 and bringing the position to 36 shares worth $516. The position accounts for ﹤0.01% of the portfolio, ranked #4122.

EverSource Wealth Advisors first reported a position in ZVRA in Q4 2024 and has held it in 7 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

EverSource Wealth Advisors held 36 shares of Zevra Therapeutics worth $516 as of Q2 2026.
EverSource Wealth Advisors bought 16 Zevra Therapeutics shares in Q2 2026, an estimated $178.
Zevra Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4122 holding.
EverSource Wealth Advisors first reported a position in Zevra Therapeutics in Q4 2024 and has held it in 7 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.